Innovent Announces NMPA Granted New Indication Approval for SULINNO(R) (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... Biopharmaceuticals, Regulatory Innovent Biologics, SULINNO , adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 23, 2020 Category: Pharmaceuticals Source Type: news

Covid-19: Anti-TNF drug adalimumab to be trialled for patients in the community, BMJ
The AVID-CC trial, funded through the Covid-19 Therapeutics Accelerator, will investigate whether adalimumab (two doses being evaluated) is effective in the treatment of adults in community care settings. Treatment will be delivered by Hospital at Home teams around the UK. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 5, 2020 Category: Consumer Health News Source Type: news

Oxford to Study Anti-inflammatory Drug Humira as Potential COVID-19 Treatment Oxford to Study Anti-inflammatory Drug Humira as Potential COVID-19 Treatment
Oxford University said on Wednesday it would study whether the world's best-selling prescription medicine, adalimumab, was an effective treatment for COVID-19 patients.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - October 1, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Arthritis drug to be trialled as Covid treatment in UK care homes
Adalimumab could counter hyper-inflammation seen in severe coronavirus casesCoronavirus – latest updatesSee all our coronavirus coverageA commonly used arthritis drug is to be trialled with care home residents who have Covid, after it was observed that those taking it for their joint pains were less likely to end up in hospital with the virus.Older people in care homes, who often have some degree of dementia, tend not to do well in hospital, where they become more confused and may pick up infections. The trial will break new ground by giving the drug to people at care homes, where they can be supervised and monitored...
Source: Guardian Unlimited Science - September 29, 2020 Category: Science Authors: Sarah Boseley Health editor Tags: Coronavirus outbreak UK news Medical research Older people Social care Health NHS Drugs Infectious diseases Science Society Source Type: news

Secukinumab Not Superior to Adalimumab in Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - September 26, 2020 Category: Orthopaedics Tags: Snapshot Source Type: news

Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
SAN FRANCISCO, U.S. and SUZHOU, China, Sept. 3, 2020 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medici... Biopharmaceuticals, Regulatory Innovent Biologics, SULINNO , adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 3, 2020 Category: Pharmaceuticals Source Type: news

Hulio (Adalimumab-fkjp njection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 16, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Hulio (adalimumab-fkjp), a Biosimilar to Humira
HERTFORDSHIRE, England and PITTSBURGH and TOKYO, July 9, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 9, 2020 Category: Drugs & Pharmacology Source Type: news

Imraldi (Adalimumab-xxxx Injection, for Subcutaneous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 18, 2020 Category: Drugs & Pharmacology Source Type: news

US regulator clears AbbVie’s $63bn deal for Allergan
Federal Trade Commission votes 3-2 to approve tie-up between makers of Botox and Humira (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 6, 2020 Category: Pharmaceuticals Source Type: news

Determining Therapeutic Range of Anti-TNF Therapies in IBD Determining Therapeutic Range of Anti-TNF Therapies in IBD
This review describes the principles and process followed to define the target therapeutic ranges for infliximab and adalimumab in the treatment of inflammatory bowel disease.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

More January U.S. price hikes take 2020 tally to over 330 drugs with higher cost
AbbVie Inc on Thursday raised the cost of rheumatoid arthritis treatment Humira, the world's top-selling medicine, joining other drugmakers that have now hiked U.S. prices of more than 330 prescription drugs for 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. (Source: Reuters: Health)
Source: Reuters: Health - January 2, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Adalimumab in Pediatric Patients With Severe Plaque Psoriasis Adalimumab in Pediatric Patients With Severe Plaque Psoriasis
This analysis reports results from the first RCT comparing the efficacy and safety of the biologic adalimumab with methotrexate for severe plaque psoriasis in children.The British Journal of Dermatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 27, 2019 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news

EMA Panel Backs Adalimumab Biosimilar Amsparity EMA Panel Backs Adalimumab Biosimilar Amsparity
The CHMP has recommended approval of Pfizer's adalimumab biosimilar (Amsparity) for treatment of certain inflammatory and autoimmune disorders in adults and children.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 16, 2019 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Biosimilar for Crohn's Noninferior to Adalimumab Biosimilar for Crohn's Noninferior to Adalimumab
A patent dispute means that the marketing of a biosimilar for patients with inflammatory bowel disease will be delayed, despite approval by the US Food and Drug Administration, investigators report.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 15, 2019 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

FDA approves Pfizer's biosimilar, ABRILADA ™ (adalimumab-afzb) for multiple inflammatory conditions
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2) (Source: World Pharma News)
Source: World Pharma News - December 2, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Abrilada (Adalimumab-afzb Injection, for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 2, 2019 Category: Drugs & Pharmacology Source Type: news

Abrilada (Adalimumab-afzb Injection, for Subcutaneous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 26, 2019 Category: Drugs & Pharmacology Source Type: news

Pfizer nabs FDA approval for Humira biosim
Abrilada is the fifth Humira biosimilar approved in the U.S. and will join generics from Mylan, Samsung Bioepis and Sandoz when AbbVie's blockbuster has its patent expire in 2023. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 19, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Abrilada™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),1 for the treatment of certain... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 18, 2019 Category: Drugs & Pharmacology Source Type: news

Statement from Sarah Yim, M.D., acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA ’s Center for Drug Evaluation and Research, on FDA’s continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product
FDA has taken another step to further foster biologics competition with the approval of 25th biosimilar, Abrilada (adalimumab - afzb), a biosimilar to Humira. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 15, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis INDIANAPOLIS, Nov. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today the 52-w... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 12, 2019 Category: Pharmaceuticals Source Type: news

China's Bio-Thera Gets Approval for Humira Biosimilar China's Bio-Thera Gets Approval for Humira Biosimilar
China's Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira (adalimumab), paving the way for the first such biosimilar to enter the world's second-largest drug market.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 9, 2019 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

China's Bio-Thera gets approval for Humira biosimilar
China's Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world's second-largest drug market. (Source: Reuters: Health)
Source: Reuters: Health - November 7, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis Arthritis Drug Falls Short in Challenge to Global Bestseller Novartis Arthritis Drug Falls Short in Challenge to Global Bestseller
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx (secukinumab) can beat the world's best-selling drug Humira (adalimumab) in treating a type of arthritis.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 5, 2019 Category: Orthopaedics Tags: Rheumatology News Source Type: news

Novartis Cosentyx ® shows encouraging results versus Humira® from first-of-its-kind head-to-head trial in psoriatic arthritis
Novartis, a leader in rheumatology and immuno-dermatology, announced results from the EXCEED head-to-head trial comparing Cosentyx® (secukinumab) to Humira®* (adalimumab) in patients with active psoriatic arthritis (PsA)[1]. While Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, it showed numerically higher results versus Humira®*[1]. (Source: World Pharma News)
Source: World Pharma News - November 4, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Novartis arthritis drug " narrowly misses " against Humira
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug, Cosentyx, can beat the world's best-selling drug Humira in treating arthritis. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 1, 2019 Category: Pharmaceuticals Source Type: news

Risk for Birth Defects Not Increased With Adalimumab
FRIDAY, Nov. 1, 2019 -- Adalimumab exposure in pregnancy does not increase the risk for birth defects, according to a study published online Oct. 18 in PLOS ONE. Christina D. Chambers, from the University of California San Diego in La Jolla, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 1, 2019 Category: Pharmaceuticals Source Type: news

Novartis arthritis drug falls short in challenge to global bestseller
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx can beat the world's best-selling drug Humira in treating a type of arthritis. (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Therapeutic IBD Drug Concentrations May Vary With Different Assays Therapeutic IBD Drug Concentrations May Vary With Different Assays
In patients with inflammatory bowel disease (IBD), concentrations of infliximab and adalimumab varied depending on whether they were assessed with the Enzyme-Linked Immunosorbent Assay (ELISA) or the Homogeneous Mobility Shift Assay (HMSA), researchers found.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2019 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Study Suggests Adalimumab Exposure in Pregnancy Does Not Increase...
602 Pregnancies Examined by the Non-Profit Organization of Teratology Information Specialists(PRWeb October 18, 2019)Read the full story at https://www.prweb.com/releases/study_suggests_adalimumab_exposure_in_pregnancy_does_not_increase_birth_defects_risk/prweb16660500.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 18, 2019 Category: Pharmaceuticals Source Type: news

Humira, Rituxan Top List of U.S. Drugs With Biggest Price Increases -report Humira, Rituxan Top List of U.S. Drugs With Biggest Price Increases -report
Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 10, 2019 Category: Infectious Diseases Tags: Public Health & Prevention News Source Type: news

Humira, Rituxan top list of U.S. drugs with biggest price increases: report
AbbVie Inc's rheumatoid arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. (Source: Reuters: Health)
Source: Reuters: Health - October 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Cyltezo (Adalimumab-ADBM Injection, for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 26, 2019 Category: Drugs & Pharmacology Source Type: news

Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions
WEDNESDAY, Sept. 25, 2019 -- In moderate-to-severe ulcerative colitis, vedolizumab is superior to adalimumab for achieving clinical remission and endoscopic improvement, but not corticosteroid-free clinical remission, and ustekinumab is superior to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 25, 2019 Category: Pharmaceuticals Source Type: news

Adalimumab procurement framework extended
NHS England has extended the procurement framework for adalimumab by four months to 31 March 2020. (Source: NHS Networks)
Source: NHS Networks - September 8, 2019 Category: UK Health Source Type: news

NHS saves £300MILLION in a year by telling doctors to stop giving out expensive branded medications
Hospitals spent £290million on adalimumab - a drug primarily used to treat arthritis but also given to patients with Crohn's disease - in 2018/19. (Source: the Mail online | Health)
Source: the Mail online | Health - August 31, 2019 Category: Consumer Health News Source Type: news

These are the top 25 costliest prescription drugs for Oregon insurers
Humira is the best-selling medicine in the world and a gold mine for drug maker AbbVie, bringing in $4.87 billion in revenue globally in the second quarter. The drug, which treats rheumatoid arthritis and Crohn's disease, costs upwards of $60,000 a year. So it may come as no surprise that Humira is on the list of the 25 most costly drugs for Oregon health insurers in 2018. The combined list is based on the rankings submitted by nine insurance comp anies and takes into account total annual spending,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 20, 2019 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news

AbbVie ’s Humira follow-up gets FDA nod
A potential new blockbuster from AbbVie has gotten the go-ahead from the FDA. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 19, 2019 Category: Pharmaceuticals Source Type: news

AbbVie prices new rheumatoid arthritis drug at $59,000 a year
AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition. (Source: Reuters: Health)
Source: Reuters: Health - August 16, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Hadlima (Adalimumab-bwwd Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 1, 2019 Category: Drugs & Pharmacology Source Type: news

Adalimumab in tight-control approach cost effective in Crohn's
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2019 Category: Drugs & Pharmacology Source Type: news

Humira biosim wins FDA approval
The clock is ticking on how much longer the world ’s best-selling drug will be free from biosimilar competition in the U.S. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 24, 2019 Category: Pharmaceuticals Source Type: news

Merck's Biosimilar to AbbVie's Humira Wins FDA Approval Merck's Biosimilar to AbbVie's Humira Wins FDA Approval
The U.S. Food and Drug Administration approved Merck& Co Inc's biosimilar to AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira (adalimumab), the health agency said on Tuesday.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 24, 2019 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Samsung Bioepis Humira biosimilar wins FDA approval
(This story corrects to show that Hadlima belongs to Samsung Bioepis not Merck& Co Inc, which is commercializing the drug in the United States) (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira
INCHEON, Korea– July 24, 2019– Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Hadlima (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab)i, for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 23, 2019 Category: Drugs & Pharmacology Source Type: news

Merck's biosimilar to AbbVie's Humira wins FDA approval
The U.S. Food and Drug Administration approved Merck& Co Inc's biosimilar to AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, the health agency said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - July 23, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

There Is No Single, Best Policy for Drug Prices
Most Americans would like the government to act, but a one-size-fits-all approach is unlikely to be the answer. (Source: NYT)
Source: NYT - July 15, 2019 Category: American Health Authors: Austin Frakt Tags: Drugs (Pharmaceuticals) Prices (Fares, Fees and Rates) Inventions and Patents Generic Brands and Products Food and Drug Administration Humira (Drug) Source Type: news

adalimumab (Humira)
Title: adalimumab (Humira)Category: MedicationsCreated: 1/22/2003 12:00:00 AMLast Editorial Review: 7/1/2019 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 1, 2019 Category: Rheumatology Source Type: news

Proactive Drug Monitoring Improves Outcomes in Kids With Crohn ’ s Proactive Drug Monitoring Improves Outcomes in Kids With Crohn ’ s
Proactive therapeutic-drug monitoring (TDM) in children with Crohn's disease on adalimumab reduces clinical exacerbations compared to reactive TDM, a randomized controlled trial shows.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news